Recovery was not confirmed in the three patients because the trial was stopped for two patients and one patient died; these patients experienced keratopathy due to an FGFR inhibitor, uveitis due to HER2-directed ADC, and dim vision (where patients see darker images) due to an HSP90 inhibitor (follow up time: 4–196 days) (Table 2 and Fig. 2A). This evidence concerns the gene ERBB2 and uveitis.